Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci (Nasdaq: ABSI) reported Q1 2026 results and program updates. ABS-201 completed four SAD cohorts and is well tolerated; preliminary PK modeling supports a targeted dosing interval of two-to-three injections over six months. MAD dosing in AGA participants has begun. ABS-202 added to preclinical pipeline. Q2 2026 preliminary data and H2 2026 interim proof-of-concept expected. Financials: revenue $0.2M, R&D $19.3M, SG&A $9.1M, net loss $29.6M, cash and equivalents $125.7M; runway into H1 2028.
Absci (Nasdaq: ABSI) granted a non-statutory option for 276,200 shares to a newly hired non-executive employee on May 1, 2026 as an inducement under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The option carries an exercise price of $4.92 (closing price on the Grant Date), a 10-year term, and vests 25% after one year with the remaining 75% vesting in approximately equal monthly installments over the following 36 months, subject to continued service and plan terms.
Absci (Nasdaq: ABSI) will report business updates and first quarter 2026 financial and operating results after market close on May 7, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. Live audio and a replay will be available on the company investor relations website.
Absci (Nasdaq: ABSI) will participate in the 25th Annual Needham Virtual Healthcare Conference.
Management is scheduled for a fireside chat on April 16, 2026 at 1:30 p.m. ET (10:30 a.m. PT). A live and archived webcast will be available on the company's investor relations website.
Absci (Nasdaq: ABSI) reported Q4 and full-year 2025 results and operational updates including dosing three SAD cohorts of ABS-201 in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo evidence of hair-growth activity.
Cash and marketable securities were $144.3M at year-end, sufficient to fund operations into H1 2028 per the company.
Absci (NASDAQ: ABSI) launched an Endometriosis Advisory Board to guide clinical development of ABS-201, an anti‑prolactin receptor antibody designed as a non‑hormonal therapy for endometriosis. The board includes experts from Yale, UCSF, Duke, and Mayo Clinic. Absci anticipates Phase 2 start in Q4 2026 and an interim readout in H2 2027. ABS-201 is formulated for subcutaneous self-administration and showed an extended half-life in non‑human primates, aiming to treat lesions without suppressing ovulation or fertility.
Absci (Nasdaq: ABSI) granted a 650,000-share non-statutory stock option to Dr. Ransi Somaratne as an inducement for his employment as Chief Medical Officer on March 3, 2026.
The option has a $2.57 exercise price (closing price on March 3, 2026), a 10-year term, and vests over four years (25% at one year, remainder in 36 monthly installments).
Absci (Nasdaq: ABSI) appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer effective March 3, 2026 to lead clinical development of its AI-designed therapeutics, including flagship ABS-201. Chief Innovation Officer Andreas Busch, Ph.D. will retire March 31, 2026 and transition to co-chair Absci’s Scientific Advisory Board.
Dr. Somaratne joins from Vertex and has prior leadership at BioMarin and Amgen, with experience on Roctavian, Repatha, and Journavx.
Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.
A webcast and live audio conference call will begin at 4:30 p.m. ET (1:30 p.m. PT), with the live stream and archived replay available via the company’s investor relations site at investors.absci.com.
Absci (Nasdaq: ABSI) will participate in multiple investor conferences in March 2026, including TD Cowen, Leerink Partners, Jefferies Biotech on the Beach, and KeyBanc Healthcare Forum. The company will host fireside chats and 1x1 meetings, with select webcasts available on its investor relations site.
Live and archived webcasts of the TD Cowen, Leerink, and KeyBanc fireside chats will be posted at investors.absci.com, and specific session dates and times are listed for investors.